ArticleOncogene2003
Pharmacogenomics: road to anticancer therapeutics nirvana?
Article in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 52 citations in OpenAlex.
- A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.Journal of neuro-oncology · 2008Trial
- The "Chinese Expert Consensus on the Clinical Application of the Chinese Modified Triplet Combination with Irinotecan (CPT-11), Oxaliplatin (LOHP), Continuous Infusion 5-Fluorouracil, and Leucovorin for Colorectal Cancer".Gastroenterology report · 2021Article
- Gene-Wise Burden of Coding Variants Correlates to Noncoding Pharmacogenetic Risk Variants.International journal of molecular sciences · 2020Article
- Hepatic expression of transcription factors affecting developmental regulation of UGT1A1 in the Han Chinese population.European journal of clinical pharmacology · 2017Article
- Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).Thoracic cancer · 2017Article
- Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.Drug design, development and therapy · 2015Article
- Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer.OncoTargets and therapy · 2014Article
- UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.Medical oncology (Northwood, London, England) · 2013Article
- Genetic variations in human glutathione transferase enzymes: significance for pharmacology and toxicology.Human genomics and proteomics : HGP · 2010Article
- EGFR-targeted therapies in lung cancer: predictors of response and toxicity.Pharmacogenomics · 2009Review
- Drug development in oncology: classical cytotoxics and molecularly targeted agents.British journal of clinical pharmacology · 2006Review
- Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks.Oncogene · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Interindividual differences in the toxicity and response to anticancer therapies are currently observed for essentially all available treatment regimens. Such 'unpredictable' drug responses are particularly dangerous in the context of anticancer agents that have narrow therapeutic indices. Pharmacogenomics attempts to elucidate the inherited basis of interindividual differences in drug response, with the eventual goal of minimizing such variability through the use of 'individualized' treatments. There are several emerging examples of genetic polymorphisms of drug-metabolizing enzymes, DNA repair genes and drug targets that have been shown to influence the toxicity and efficacy of anticancer treatment. This review discusses the role of genetic variants of UGT1A1, TS and EGFR to exemplify the potential impact of phramacogenomics on the field of anticancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.